Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.

Besides producing novel drugs based on first-gen psychedelics such as DMT, 5-MeO-DMT and mescaline, Biomind seeks to create innovative nanotech delivery systems to treat psychiatric and neurological conditions.

The clinical …

Full story available on